Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01760889 · ClinicalTrials.gov registry record · Phase 3
SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia
A Phase 3 study, sponsored by Shire.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1
- Enrollment target
NCT01760889: Clinical Trial Phase 3 study, sponsored by Shire.
NCT01760889 is a Phase 3 study that was terminated before completion, run by Shire. The registered enrollment target is 1 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01760889, a Phase 3 study, was terminated before completion, sponsored by Shire.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine whether SPD489 low dose range (40, 80, or 100mg) and high dose range (120, 140, or 160mg) are effective in the treatment of Negative Symptoms.
Interventions
- DRUG Placebo
- DRUG SPD489 low dose range (40mg, 80mg, and 100mg)
- DRUG SPD489 high dose range (120mg, 140mg and 160mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2013-02-01 |
| Est. Completion | 2013-04-01 |
| Phase | Phase 3 |
Why NCT01760889 stopped before completion
NCT01760889 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01760889 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01760889 about?
NCT01760889 is a clinical study titled "SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia". The primary purpose of this study is to determine whether SPD489 low dose range (40, 80, or 100mg) and high dose range (120, 140, or 160mg) are effective in the treatment of Negative Symptoms.
What is the current status of trial NCT01760889?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1 participants. The study started on 2013-02-01. Estimated completion is 2013-04-01.
What interventions are being tested in trial NCT01760889?
The interventions under investigation include: Placebo (DRUG), SPD489 low dose range (40mg, 80mg, and 100mg) (DRUG), SPD489 high dose range (120mg, 140mg and 160mg) (DRUG).
Who is sponsoring clinical trial NCT01760889?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01760889's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI